{"id":66469,"date":"2026-05-27T20:38:58","date_gmt":"2026-05-27T12:38:58","guid":{"rendered":"https:\/\/flcube.com\/?p=66469"},"modified":"2026-05-27T20:38:59","modified_gmt":"2026-05-27T12:38:59","slug":"shanghai-henlius-biotech-initiates-phase-ii-iii-study-of-pimurutamab-hlx07-combination-therapy-in-first-line-advanced-squamous-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66469","title":{"rendered":"Shanghai Henlius Biotech Initiates Phase II\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Henlius Biotech Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2696:HKG\">HKG: 2696<\/a>) announced the dosing of the first patient in a <strong>Phase II\/III clinical study<\/strong> evaluating its investigational <strong>pimurutamab (HLX07)<\/strong> in combination with <strong>HanSiZhuang (serplulimab)<\/strong> plus chemotherapy for <strong>first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC)<\/strong> in China.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-program\" class=\"wp-block-heading\">Clinical Development Program<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase II\/III (seamless design)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line advanced squamous NSCLC<\/td><\/tr><tr><td><strong>Combination Regimen<\/strong><\/td><td>HLX07 + HanSiZhuang (serplulimab) + chemotherapy<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Treatment-na\u00efve advanced sqNSCLC patients in China<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>Progression-free survival (PFS) and overall survival (OS)<\/td><\/tr><tr><td><strong>Study Status<\/strong><\/td><td>First patient dosed \u2013 active recruitment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-portfolio-overview\" class=\"wp-block-heading\">Product Portfolio Overview<\/h2>\n\n\n\n<h3 id=\"h-hlx07-pimurutamab\" class=\"wp-block-heading\">HLX07 (Pimurutamab)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Recombinant humanized anti-EGFR monoclonal antibody (mAb)<\/li>\n\n\n\n<li><strong>Target Indication:<\/strong> Advanced solid tumors<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Investigational \u2013 not yet approved<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> EGFR inhibition to block tumor growth signaling pathways<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-hansizhuang-serplulimab\" class=\"wp-block-heading\">HanSiZhuang (Serplulimab)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Innovative anti-PD-1 monoclonal antibody (mAb)<\/li>\n\n\n\n<li><strong>Regulatory Status:<\/strong> <strong>Already approved<\/strong> for marketing in China<\/li>\n\n\n\n<li><strong>Approved Indications:<\/strong><\/li>\n\n\n\n<li>First-line sqNSCLC (in combination with chemotherapy)<\/li>\n\n\n\n<li>Extensive-stage small cell lung cancer (ES-SCLC)<\/li>\n\n\n\n<li>Esophageal squamous cell carcinoma (ESCC)<\/li>\n\n\n\n<li>Non-squamous NSCLC (nsqNSCLC)<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-clinical-innovation\" class=\"wp-block-heading\">Strategic Rationale &amp; Clinical Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual-Target Approach:<\/strong> Combines EGFR inhibition (HLX07) with PD-1 blockade (HanSiZhuang) plus standard chemotherapy<\/li>\n\n\n\n<li><strong>Rationale:<\/strong> EGFR expression is common in sqNSCLC; combining targeted therapy with immunotherapy may enhance anti-tumor response<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Leverages Henlius&#8217; already-approved anti-PD-1 backbone with novel anti-EGFR agent<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Addresses approximately 40% of NSCLC cases that are squamous subtype<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Limited targeted therapy options currently available for sqNSCLC compared to non-squamous NSCLC<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NSCLC Market Size:<\/strong> $25+ billion global market with significant growth in immunotherapy combinations<\/li>\n\n\n\n<li><strong>China Focus:<\/strong> Study conducted exclusively in China initially, leveraging HanSiZhuang&#8217;s established regulatory approval<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Differentiates from existing EGFR inhibitors by combining with proprietary anti-PD-1 therapy<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Potential to expand HanSiZhuang&#8217;s already-approved sqNSCLC indication with enhanced efficacy through triple combination<\/li>\n\n\n\n<li><strong>Development Timeline:<\/strong> Phase II\/III results expected 2028, with potential regulatory submission following positive outcomes<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-pipeline-integration\" class=\"wp-block-heading\">Pipeline Integration<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This study represents Henlius&#8217; strategic expansion of its oncology portfolio by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Maximizing value from approved HanSiZhuang platform<\/li>\n\n\n\n<li>Developing novel combination regimens for hard-to-treat indications<\/li>\n\n\n\n<li>Establishing leadership in Chinese lung cancer therapeutics<\/li>\n\n\n\n<li>Creating potential for international expansion following domestic success<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market expectations for HLX07 and combination therapies. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052600653_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026052600653_c.\"><\/object><a id=\"wp-block-file--media-83c19007-3e74-4166-a555-685c9719f82e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052600653_c.pdf\">2026052600653_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/2026052600653_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-83c19007-3e74-4166-a555-685c9719f82e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,270,862],"class_list":["post-66469","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-henlius-biotech","tag-hkg-2696"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shanghai Henlius Biotech Initiates Phase II\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a Phase II\/III clinical study evaluating its investigational pimurutamab (HLX07) in combination with HanSiZhuang (serplulimab) plus chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC) in China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66469\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai Henlius Biotech Initiates Phase II\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC\" \/>\n<meta property=\"og:description\" content=\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a Phase II\/III clinical study evaluating its investigational pimurutamab (HLX07) in combination with HanSiZhuang (serplulimab) plus chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC) in China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66469\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T12:38:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-27T12:38:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66469#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66469\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai Henlius Biotech Initiates Phase II\\\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC\",\"datePublished\":\"2026-05-27T12:38:58+00:00\",\"dateModified\":\"2026-05-27T12:38:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66469\"},\"wordCount\":413,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Henlius Biotech\",\"HKG: 2696\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66469#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66469\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66469\",\"name\":\"Shanghai Henlius Biotech Initiates Phase II\\\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-27T12:38:58+00:00\",\"dateModified\":\"2026-05-27T12:38:59+00:00\",\"description\":\"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a Phase II\\\/III clinical study evaluating its investigational pimurutamab (HLX07) in combination with HanSiZhuang (serplulimab) plus chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC) in China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66469#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66469\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66469#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai Henlius Biotech Initiates Phase II\\\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai Henlius Biotech Initiates Phase II\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a Phase II\/III clinical study evaluating its investigational pimurutamab (HLX07) in combination with HanSiZhuang (serplulimab) plus chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC) in China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66469","og_locale":"en_US","og_type":"article","og_title":"Shanghai Henlius Biotech Initiates Phase II\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC","og_description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a Phase II\/III clinical study evaluating its investigational pimurutamab (HLX07) in combination with HanSiZhuang (serplulimab) plus chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC) in China.","og_url":"https:\/\/flcube.com\/?p=66469","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-27T12:38:58+00:00","article_modified_time":"2026-05-27T12:38:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66469#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66469"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai Henlius Biotech Initiates Phase II\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC","datePublished":"2026-05-27T12:38:58+00:00","dateModified":"2026-05-27T12:38:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66469"},"wordCount":413,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Henlius Biotech","HKG: 2696"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66469#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66469","url":"https:\/\/flcube.com\/?p=66469","name":"Shanghai Henlius Biotech Initiates Phase II\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-27T12:38:58+00:00","dateModified":"2026-05-27T12:38:59+00:00","description":"Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in a Phase II\/III clinical study evaluating its investigational pimurutamab (HLX07) in combination with HanSiZhuang (serplulimab) plus chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC) in China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66469#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66469"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66469#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai Henlius Biotech Initiates Phase II\/III Study of Pimurutamab (HLX07) Combination Therapy in First-Line Advanced Squamous NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66469","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66469"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66469\/revisions"}],"predecessor-version":[{"id":66471,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66469\/revisions\/66471"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}